Oncology: Camino Pharma programs integrate novel biological insights with innovative chemical strategies to target two major classes of cancer signaling proteins: protein tyrosine phosphatases (PTPs) and G-protein-coupled receptors (GPCRs). Discovery of selective and potent small molecule inhibitors of these important targets has been challenging. Camino Pharma has overcome these challenges by discovering novel allosteric mechanisms that regulate PTP and GPCR function, and has identified small molecules that selectively modulate these mechanisms.

Brain Disorders: Camino Pharma focuses on the discovery and development of novel allosteric modulators of the metabotropic Glutamate Receptor 2 (mGlu2) for two psychiatric indications, addiction and treatment resistant depression. The program focusing on addiction has obtained funding from the National Institute of Drug Abuse (NIDA) through a collaborative UO1 grant together with the Sanford Burnham Prebys Medical Research Institute and the University of California, San Diego. The program focusing on treatment-resistant depression will advance several novel chemical series of selective negative allosteric modulators with the potential to mimic ketamine-like anti-depressive activity without the side-effects.